Le rapport financier annuel 2015 peut être consulté sur le site internet de la société www.cellnovo.com rubrique Investisseurs / Documentation.
Sophie Baratte, Chief Executive Officer of Cellnovo, commented: “2015 has been a pivotal year for Cellnovo. Since undertaking our initial public offering on Euronext last July, we have achieved a number of key commercial milestones for our unique all-in-one diabetes management system.
The project, named PEPPER (Patient Empowerment through Predictive Personalised decision support), has a budget of nearly EUR 4 million and brings together leading UK and European universities and companies to research and develop technology that will help to improve the self-management of people with Type 1 diabetes.
Cellnovo will build in the Accu-Chek® Aviva or Accu-Chek® Performa monitoring platforms into its newly developed, next generation e-connected handset which was CE-marked earlier this month. The Roche BGM platform will replace the LifeScan OneTouch® Vita BGM currently used. The redesign of the handset will also enable an increase in productivity at Cellnovo’s manufacturing site, due to a reduced assembly time.
Thierry Moulin joins Cellnovo from the multinational biopharmaceutical company Cellectis, where he served as Chief Financial Officer since 2014, overseeing a $228 million fundraise via a public listing on the Nasdaq in March 2015. During his time at Cellectis he also contributed to an extensive programme of restructuring through mergers, divestitures and reallocation of resources.
The artificial pancreas is designed to automatically monitor and regulate blood-sugar levels in people with Type 1 diabetes through the delivery of insulin.
Mr. Masoud has a proven track record of bringing new medical technologies from concept to product release with a system perspective. Working in the US and Europe, he is recognized for his consistent results and effective leadership in technology and product development by leading multi-functional international teams.
A live webcast of Cellnovo’s presentation can be accessed via the following link: http://wsw.com/webcast/canaccord20/clnv.pa. An archived audio of the discussion will also be available on Cellnovo’s website for 90 days.
Sophie Baratte, CEO of Cellnovo, comments: “We are very pleased with our sales growth over the first 9 months of 2015, which validates our business strategy. Since our recent IPO, we continue our commercial development efforts in France and the UK, confirming the strong interest of both medical community and patients for our all-in-one Diabetes Management System. This growing adoption of our patch pumps makes us confident in our top-line growth in the next quarters.”
Cellnovo member of the Euronext indexes CAC® Small, CAC® Mid & Small and CAC® All-Tradable
The inclusion of Cellnovo shares in these indexes is the result of a share liquidity analysis made by Euronext on the basis of two criteria: amount of capital traded and free float market capitalization. The scope of the liquidity criteria highlights the marked interest from investors for Cellnovo, despite the recent listing of the company. These indexes are used as references by a number of mutual and SICAV open-end investment funds.
Furthermore, in accordance with Article 631-10 of the Autorité des marchés financiers ("AMF") General Rules, Société Générale, acting as stabilizing agent, has conducted stabilizing operations on the Cellnovo shares (FR0012633360 – CLNV) that started on July 10, 2015 and ended on the same day, at a price of €10.63 per share.
The Open Price Offering and the Global Placement price has been set at €10.63 per share. The total number of shares issued will be 2,969,557, resulting in a capital increase of €31.56 million. Based on a total of 10,683,873 shares to be admitted to the market and a price of €10.63 per share, Cellnovo’s market capitalization will be €113.6 million at the end of the operation. Cellnovo has granted Société Générale acting in the name and on behalf of the banking syndicate an overallotment option, exercisable from today until August 7, 2015 included, on a maximum of 80,000 new shares or approximately €0.85 million.
Following the registration of its document de base under number I.15-008 on February 27, 2015, the Autorité des marchés financiers (AMF) granted visa n°15-313 on June 26th, 2015, for the prospectus relative to the listing of Cellnovo.
Cellnovo already launched the marketing of its insulin patch pump system in the United Kingdom and France in 2014 via a direct sales force. Its commercialization is now being extended to other countries via a network of key distributors.
Cellnovo is announcing that it is joining the Diabeloop© Artificial Pancreas program by supplying its unique patch pump and mobile diabetes management technologies. Diabeloop© is a research association between the CERIDT, a general interest leading diabetes research institution and service provider in France and the CEA-LETI, the French government’s main research and development institution. Ten leading French university hospitals are participating in this project. The Cellnovo R&D team will be joining the Diabeloop© research consortium by further developing its pump and handset software to allow the development of an artificial pancreas system. The overall Diabeloop© project is currently the subject of a special financing application with the French government in the form of an FUI (Fonds Unique Interministériel).
The registration of the document de base is the first step towards the Initial Public Offering of Cellnovo’s shares on the regulated market of Euronext in Paris, subject to market conditions and regulatory pre-requisites, in particular the AMF’s visa on the prospectus to be prepared in respect of the proposed transaction.